BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating BHB810, a novel, ...

Astellas Pharma (TSE:4503) has started dosing the first patient in a Phase 3 trial of ASP2138 for CLDN18.2-positive and ...

I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with ...

The study partially fulfills a goal set in the company's latest strategic plan that emphasizes late-stage and pivotal trials.

Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial. This is an ASCO Meeting Abstract from ...

Add Yahoo as a preferred source to see more of our stories on Google. Innovent's CLN18.2-targeting ADC Takeda's $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs ...

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy. The first patient has been dosed in a phase ...

A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer. Long-term follow up of selinexor maintenance in patients ...

Astellas begins patient dosing in in phase 3 study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma: Toky ...